Neumora Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neumora Therapeutics advances neuroscience pipeline with promising MDD treatment

Neumora Therapeutics is strategically positioned with a focus on brain disease treatments, a diversified pipeline, and a strong cash position supporting operations.
While facing challenges in managing expenses and meeting market expectations, the company's proactive approach and promising pipeline offer opportunities for growth and innovation.
Investors should monitor Neumora's progress on upcoming clinical catalysts and the successful development of Navacaprant for various indications to gauge future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

The lead Neumora Therapeutics, Inc. product candidate, Navacaprent, has shown promise in treating major depressive disorder, MDD, and bipolar depression. The lead product candidate, Navacaprent, is a selective kappa opioid receptor antagonist that has shown promise in major depressive disorder and bipolar depression. The company has other value-driving product candidates in various stages of development for conditions like Alzheimer's disease, schizophrenia, and Parkinson's disease.

Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades

Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

Renaissance IPO ETF

Camden Property

The IPO market in 2023 has been anything but hot. After a record-breaking year in 2021, the appetite for new listings has cooled down significantly, first in 2022 and continuing into the current year.

Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)

Amgen

Neumora Therapeutics stock advanced as much as 16% in Wednesday morning's trade after it was revealed that Amgen Inc (NASDAQ:AMGN) holds a material stake in the company. Amgen was an investor in Neumora's IPO last week, adding to an existing holding, to give it a 23.2% stake in the neuroscience drug discovery company, according to a filing.

Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer

Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.

Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics

Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.

Why Shares of Neumora Therapeutics Slumped This Week

WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Neumora. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neumora, are expected to be approximately $250 million. In addition, Neumora has granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.” The initial public offering is expected to close on September 19, 2023, subject to the satisfaction of customary closing conditions.

Neumora Therapeutics Announces Pricing of Initial Public Offering

Neumora Therapeutics, Inc. plans to raise $250 million in an IPO to fund the development of drug treatments for psychiatric disorders and neurological diseases. The company has a major collaboration with Amgen and is in Phase 3 trials for its lead candidate. Neumora Therapeutics is well-capitalized and has a strong investor syndicate, making it a compelling investment opportunity for patient life science investors.

IPO Update: Neumora Therapeutics Seeks $250 Million U.S. IPO

News for Neumora Therapeutics Inc Stock (NMRA)